Advertisement
Clinical Breast Cancer Home
Advanced searchSave search
Research Article| Volume 4, SUPPLEMENT 3, S121-S126, January 2004

Rationale and Clinical Trial Design for Evaluating Gemcitabine as Neoadjuvant and Adjuvant Therapy for Breast Cancer

DOI:https://doi.org/10.3816/CBC.2004.s.006
Rationale and Clinical Trial Design for Evaluating Gemcitabine as Neoadjuvant and Adjuvant Therapy for Breast Cancer
Previous ArticleGemcitabine and Trastuzumab Combinations for Patients with Metastatic Breast Cancer Overexpressing HER2/neu
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Over the past 30 years, much progress has been made in adjuvant chemotherapy for patients with earlystage breast cancer. The introduction of anthracyclines and, recently, taxanes has significantly improved the efficacy of adjuvant chemotherapy and has provided useful insight regarding future development of even more efficacious regimens. However, despite significant progress, there remains considerable room for improvement. Although the manipulation of chemotherapy doses has not been found to be a successful strategy, manipulation of the interval of chemotherapy administration recently showed promise. It appears, nonetheless, that introducing new chemotherapy agents into the adjuvant setting is a more promising strategy than attempting to optimize the dose and schedule of existing agents. Gemcitabine has demonstrated significant antitumor activity in patients with advanced breast cancer when used either as a single agent or in combination with other active drugs (as a doublet or a triplet). Most of the available information to date has been obtained by combining gemcitabine with anthracyclines and/or taxanes. This approach has shown considerable antitumor activity and a reasonable toxicity profile, making it an important strategy for developing new adjuvant and neoadjuvant chemotherapy regimens. Several currently ongoing and planned adjuvant trials are incorporating gemcitabine (either sequentially or in combination) into anthracycline/taxane regimens. These trials will be important in establishing a role for this agent in the adjuvant setting and will hopefully lead to the development of more effective adjuvant chemotherapy regimens in the future.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
        Lancet. 1998; 352: 930-942
        • Henderson IC
        • Berry DA
        • Demetri GD
        • et al.
        Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
        J Clin Oncol. 2003; 21: 976-983
        • Mamounas EP
        • Bryant J
        • Lembersky BC
        • et al.
        Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28.
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #12).: 4
        • Blackstein M
        • Vogel CL
        • Ambinder R
        • et al.
        Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial.
        Oncology. 2002; 62: 2-8
        • Nabholtz J-M
        • Pienkowski T
        • Mackey J
        • et al.
        Phase III trial comparing TAC (docetaxel, doxorubincin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 0001 study.
        Proc Am Soc Clin Oncol. 2002; 21 (Abstract #141).: 36a
        • Fisher B
        • Anderson S
        • Wickerham DL
        • et al.
        Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.
        J Clin Oncol. 1997; 15: 1858-1869
        • Fisher B
        • Anderson S
        • DeCillis A
        • et al.
        Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25.
        J Clin Oncol. 1999; 17: 3374-3388
        • Citron ML
        • Berry DA
        • Cirrincione C
        • et al.
        Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
        J Clin Oncol. 2003; 21: 1431-1439
        • Piccart-Gebhart MJ
        Mathematics and oncology: a match for life?.
        J Clin Oncol. 2003; 21: 1425-1428
        • Green M
        • Buzdar A
        • Smith T
        • et al.
        Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q3 wk) P therapy (tx) followed by FAC-final results of a prospective phase III randomized trial.
        Proc Am Soc Clin Oncol. 2002; 21 (Abstract #135).: 35a
        • Heinemann V
        Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
        Oncology. 2003; 64: 191-206
        • Brodowicz T
        • Kostler WJ
        • Moslinger R
        • et al.
        Single-agent gemcitabine as second-and third-line treatment in metastatic breast cancer.
        Breast. 2000; 9: 338-342
        • Carmichael J
        • Possinger K
        • Phillip P
        • et al.
        Advanced breast cancer: a phase II trial with gemcitabine.
        J Clin Oncol. 1995; 13: 2731-2736
        • Possinger K
        • Kaufmann M
        • Coleman R
        • et al.
        Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.
        Anticancer Drugs. 1999; 10: 155-162
        • Schmid P
        • Akrivakis K
        • Flath B
        • et al.
        Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer.
        Anticancer Drugs. 1999; 10: 625-631
        • Smorenburg CH
        • Bontenbal M
        • Seynaeve C
        • et al.
        Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane.
        Breast Cancer Res Treat. 2001; 66: 83-87
        • Spielmann M
        • Llombart-Cussac A
        • Kalla S
        • et al.
        Single-agent gemcitabine is active in previously treated metastatic breast cancer.
        Oncology. 2001; 60: 303-307
        • Perez-Manga G
        • Lluch A
        • Alba E
        • et al.
        Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial.
        J Clin Oncol. 2000; 18: 2545-2552
        • Campone M
        • Viens P
        • Dieras V
        • et al.
        Gemzar (G) and epirubicin (E) in patients with metastatic breast cancer: Results of a phase II trial.
        Proc Am Soc Clin Oncol. 2001; 20 (Abstract #1940).: 48b
        • Laufman LR
        • Spiridonidis CH
        • Pritchard J
        • et al.
        Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
        Ann Oncol. 2001; 12: 1259-1264
        • Colomer R
        • Llombart A
        • Lluch A
        • et al.
        Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.
        Semin Oncol. 2000; 27: 20-24
        • Delfino C
        • Riva Gonzales L
        • Mickiewicz E
        Gemcitabine plus paclitaxel administered as first-line chemotherapy for patients with advanced breast cancer.
        Proc Am Soc Clin Oncol. 2002; 21 (Abstract #2025).: 53b
        • Genot JY
        • Tubiana-Hulin M
        • Tubiana-Mathieu N
        • et al.
        Gemcitabine and paclitaxel in metastatic breast cancer: A phase II study in the first-line setting.
        Proc Am Soc Clin Oncol. 2002; 21 (Abstract #2002).: 48b
        • Sanchez P
        • Medina MB
        • Mohedano N
        • et al.
        Results from a phase II study of gemcitabine in combination with paclitaxel in metastatic breast cancer.
        Ann Oncol. 1998; 9 (Abstract #77P).: 16
        • Murad AM
        • Guimaraes RC
        • Aragao BC
        • et al.
        Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer.
        Am J Clin Oncol. 2001; 24: 264-268
        • Gomez H
        • Kahatt C
        • Falcon S
        • et al.
        A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: a preliminary report.
        Semin Oncol. 2001; 28: 57-61
        • Forastiere AA
        • Hakes TB
        • Wittes JT
        • et al.
        Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules.
        Am J Clin Oncol. 1982; 5: 243-247
        • Ostrow S
        • Egorin M
        • Aisner J
        • et al.
        High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy.
        Cancer Clin Trials. 1980; 3: 23-27
        • Yap HY
        • Salem P
        • Hortobagyi GN
        • et al.
        Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer.
        Cancer Treat Rep. 1978; 62: 405-408
        • Peters GJ
        • Bergman AM
        • Ruiz van Haperen VW
        • et al.
        Interaction between cisplatin and gemcitabine in vitro and in vivo.
        Semin Oncol. 1995; 22: 72-79
        • Nagourney RA
        • Su YZ
        • Link J
        • et al.
        Gemcitabine synergy with cisplatin. Clinical and laboratory correlates.
        Proc Am Soc Clin Oncol. 1998; 39 (Abstract #2118).: 310
        • Nagourney RA
        • Link JS
        • Blitzer JB
        • et al.
        Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients.
        J Clin Oncol. 2000; 18: 2245-2249
        • Calderillo Ruiz GC
        • Fuentes de la Pena H
        • Meza FA
        • et al.
        Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.
        Proc Am Soc Clin Oncol. 2001; 20 (Abstract #1988).: 60b
        • Chaudhry S
        • Abdel-Rahman HA
        • Patil R
        • et al.
        Prospective phase II study of weekly cisplatin-gemcitabine in refractory metastatic breast cancer.
        Proc Am Soc Clin Oncol. 2000; 19 (Abstract #430).: 111a
        • Burch PA
        • Mailliard JA
        • Hillman DW
        • et al.
        Phase II study of gemcitabine and cisplatin in patients with metastatic breast cancer and failure on prior chemotherapy: A North Central Cancer Treatment Group trial.
        Breast Cancer Res Treat. 2000; 64 (Abstract #322).: 81
        • Doroshow JH
        • Tetef M
        • Margolin K
        • et al.
        Significant activity of gemcitabine and cisplatin in both heavily and minimally pretreated metastatic breast cancer patients: A California Cancer Consortium/Loyala University Chicago Trial.
        Proc Am Soc Clin Oncol. 2000; 19 (Abstract #609H).: 155a
        • Kornek G
        • Raderer M
        • Fiebiger W
        • et al.
        Treatment of advanced breast cancer with docetaxel and gemcitabine + human granulocyte colony-stimulating factor.
        Proc Am Soc Clin Oncol. 2001; 20 (Abstract #1978).: 57b
        • Pelegri A
        • Calvo L
        • Florian J
        • et al.
        Every-other-week combination of gemcitabine and docetaxel as first-line therapy in advanced breast cancer patients: preliminary results from a phase II trial.
        Breast Cancer Res Treat. 2001; 69 (Abstract #356).: 3
        • Brandi M
        • Giotta F
        • Vici P
        • et al.
        Salvage chemotherapy with docetaxel and gemcitabine in metastatic breast cancer: preliminary results of a multicenter phase II trial of GOIM (Gruppo Oncologico dell'Italia Meridionale).
        Proc Am Soc Clin Oncol. 2001; 20 (Abstract #1956).: 52b
        • Mavroudis D
        • Malamos N
        • Alexopoulos A
        • et al.
        Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
        Ann Oncol. 1999; 10: 211-215
        • Fountzilas G
        • Nicolaides C
        • Bafaloukos D
        • et al.
        Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study.
        Cancer Invest. 2000; 18: 503-509
        • Alexopoulos A
        • Kandilis K
        • Stavrakakis J
        • et al.
        Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic cancer.
        Proc Am Soc Clin Oncol. 2001; 20 (Abstract #1945).: 49b
        • Theodossiou C
        • Cook JA
        • Fisher J
        • et al.
        Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines.
        Int J Oncol. 1998; 12: 825-832
        • Kroep JR
        • Tolis C
        • Voorn DA
        • et al.
        Paclitaxel and gemcitabine cell-cycle interactions in non-small-cell lung cancer cell lines.
        Proc Am Soc Clin Oncol. 1999; 40 (Abstract #4472).: 678
        • Kroep JR
        • Giaccone G
        • Voorn DA
        • et al.
        Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
        J Clin Oncol. 1999; 17: 2190-2197
        • O'Shaughnessy J
        • Nag S
        • Calderillo-Ruiz G
        • et al.
        Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Interim results of a global phase III study.
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #25).: 7
        • Sanchez-Rovira P
        • Jaen A
        • Gonzalez E
        • et al.
        Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.
        Oncology (Huntingt). 2001; 15: 44-47
        • Conte PF
        • Gennari A
        • Donati S
        • et al.
        Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
        Breast Cancer Res Treat. 2001; 68: 171-179
        • Mazzoni F
        • Donati S
        • Gennari A
        • et al.
        A multicentric phase II trial of gemcitabine plus epirubicin plus taxol (GET) as first-line chemoherapy for metastatic breast cancer.
        Breast Cancer Res Treat. 2000; 64 (Abstract #347).: 87
        • Zielinski C
        • Beslija S
        • Mrsic-Krmpotic Z
        • et al.
        Gemcitabine/epirubicin/paclitaxel (GET) vs 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer (MBC): Demographics of a randomized, multicenter phase III trial of the Central European Cooperative Oncology Group (CEGOG).
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #26).: 7
        • Fisher B
        • Bryant J
        • Wolmark N
        • et al.
        Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
        J Clin Oncol. 1998; 16: 2672-2685
        • Fisher B
        • Mamounas EP
        Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer.
        J Clin Oncol. 1995; 13: 537-540
        • van der Hage JA
        • van de Velde CJ
        • Julien JP
        • et al.
        Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
        J Clin Oncol. 2001; 19: 4224-4237
        • Wolmark N
        • Wang J
        • Mamounas E
        • et al.
        Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.
        J Natl Cancer Inst Monogr. 2001; : 96-102
        • Bear H
        The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: preliminary results from NSABP protocol B-27.
        Breast Cancer Res Treat. 2001; 69 (Abstract #215).: 210
        • von Minckwitz G
        • Raab G
        • Blohmer JU
        • et al.
        Primary chemotherapy adapted on in-vivo-chemosensitivity in patients with primary breast cancer. The pilot GEPARTRIO study.
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #85).: 22
        • von Minckwitz G
        • Raab M
        • Schuette N
        • et al.
        Dose-dense versus sequential adriamycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2, M0) -primary endpoint analysis of the GEPARDUO-study.
        Proc Am Soc Clin Oncol. 2002; 21 (Abstract #168).: 43a
        • Gianni L
        • Baselga J
        • Eiermann W
        • et al.
        First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease.
        Proc Am Soc Clin Oncol. 2002; 21 (Abstract #132).: 34a
        • Smith IC
        • Heys SD
        • Hutcheon AW
        • et al.
        Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.
        J Clin Oncol. 2002; 20: 1456-1466
        • Pusztai L
        • Ayers M
        • Simman FW
        • et al.
        Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer.
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #1).: 1
        • Chang JCN
        • Wooten EC
        • Tsimelzon A
        • et al.
        Gene expression patterns for de novo and acquired docetaxel resistance in patients with locally advanced breast cancer.
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #32).: 9
        • Sanchez-Rovira P
        • Ramirez C
        • Duenas R
        • et al.
        HER2 status as a predictive factor for pathological complete response in primary breast cancer patients with gemcitabine-adriamycin-taxol as neoadjuvant treatment.
        Breast Cancer Res Treat. 2001; 69 (Abstract #240).: 246
        • Hamm J
        • Wilson J
        • Lembersky BC
        • et al.
        Neoadjuvant chemotherapy with gemcitabine (G), epirubicin (E), and paclitaxel (T) in locally advanced breast cancer (LABC): a phase II trial of the NSABP Foundation Research Group.
        Breast Cancer Res Treat. 2003; 82 (Abstract #235).: S53

      Article info

      Publication history

      Accepted: December 22, 2003
      Received in revised form: December 10, 2003
      Received: October 31, 2003

      Footnotes

      Electronic forwarding or copying is a violation of US and International Copyright Laws.

      Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Cancer Information Group, ISSN #1526-8209, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.

      Identification

      DOI: https://doi.org/10.3816/CBC.2004.s.006

      Copyright

      © 2004 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX